Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association.
Recent Posts
Event tomorrow: Improving access and affordability for America’s seniors
By Andrew Powaleny | May 7, 2019
Medicare Parts B and D have played an important role in providing seniors with access to the lifesaving treatments they need and have been successful in delivering value to both the health care...
Read More
New report shows more than 160 medicines in development for diabetes and related conditions
By Andrew Powaleny | April 24, 2019
Diabetes represents a significant public health issue in the U.S. It affects more than 30 million Americans, including around 7.2 million who are undiagnosed. Additionally, there are close to 1.5...
Read More
New report shows nearly 20 innovative medicines in development for sickle cell disease
By Andrew Powaleny | April 2, 2019
Sickle cell disease (SCD) is the most common inherited blood disorder in the United States, afflicting nearly 100,000 Americans. Patients with SCD have sickle-shaped red blood cells, which have...
Read More
130 medicines in development for asthma, allergies and other respiratory diseases
By Andrew Powaleny | February 21, 2019
Millions of Americans suffer from respiratory diseases, including Asthma and chronic obstructive pulmonary disease (COPD). Together, these two diseases affect the day-to-day lives of over 40...
Read More
Putting 2018 medicine approvals in context
By Andrew Powaleny | January 23, 2019
Last year, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved a record number of novel new medicines with 59 new molecular entities (NMEs). While...
Read More
New report shows nearly 300 cell and gene therapies in development
By Andrew Powaleny | December 6, 2018
Fifty years ago, the idea of altering a gene to treat or even cure a disease was considered science fiction. Today, cell and gene therapy are transforming treatment options for some patients and...
Read More
World AIDS Day 2018: Hope for the future
By Andrew Powaleny | December 1, 2018
Each year, I write to commemorate World AIDS Day which is now in its 30th year spotlighting patients living with HIV and those we’ve sadly lost to AIDS-related illnesses.
Read More
New report shows more than 300 skin disease medicines in development
By Andrew Powaleny | September 25, 2018
More than 100 million Americans – one third of the U.S. population – suffer from skin conditions.
Read More
Disrupting Alzheimer's
By Andrew Powaleny | September 10, 2018
We are living in a new era of medicine, where treatments and even cures once believed to be impossible are today a reality. But this immense progress does not apply universally and there have been...
Read More
Here’s how America’s biopharmaceutical companies lead the way in development of innovative new medicines
By Andrew Powaleny | July 25, 2018
In today’s new era of medicine, America’s biopharmaceutical companies are conducting some of the most complex and difficult research in the world to develop innovative treatments for patients.
Read More
Medicare Monday (100)
340B Spotlight (41)
Cost & Consequence (0)
